Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lucid-21-302 · Lucid-21

Small molecule · Inhibitor · developed by Quantum Biopharma

Phase 1 Most advanced trial (none active)

QNTM Developer

1 Registered trials

What is Lucid-21-302?

Lucid-21-302 is a small molecule inhibitor of hypercitrullination.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Lucid-21
Drug type: Small molecule
Mechanism: Inhibitor
Developer: Quantum Biopharma (QNTM, QUCY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05821387	Phase 1	Healthy Participants	Completed	QNTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Participants

More from Quantum Biopharma

Firibastat Phase 3 FSD-201 Phase 2

Sources

ClinicalTrials.gov NCT05821387

Updated Oct 3, 2026. Something wrong or missing? Report it on the QNTM page.

Follow QNTM, the company behind Lucid-21-302

See QNTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

QNTM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z